Osteopontin regulates ubiquitin-dependent degradation of stat1 in murine mammary epithelial tumor cells

Neoplasia

Volumn 9, Issue 9, 2007, Pages 699-706

  Gao, Chengjiang ^a   Mi, Zhiyong ^a   Guo, Hongtao ^a   Kuo, Paul C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Interferon; p21; Proteasome; SLIM; Ubiquitin

Indexed keywords

GAMMA INTERFERON; LIM PROTEIN; OSTEOPONTIN; PROTEIN P21; STAT1 PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CARCINOGENESIS; CONTROLLED STUDY; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR CELL; TUMOR GROWTH;

EID: 34948881798     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07463     Document Type: Article

References (28)

1. Denhardt DT, Noda M, O'Regan AW, Pavlin D, and Berman JS (2001). Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107, 1055-1061.
2. Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, and Yamamoto S (1994). Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 303, 255-262.
3. O'Regan A and Berman JS (2000). Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 81, 373-390.
4. Weber GF (2001). The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552, 61-85.
5. Wai PY and Kuo PC (2004). The role of osteopontin in tumor metastasis. J Surg Res 121, 228-241.
6. Gao C, Guo H, Mi Z, Grusby MJ, and Kuo PC (2007). Osteopontin induces ubiquitin-dependent degradation of Stat1 in RAW264.7 murine macrophages. J Immunol 178, 1870-1881.
7. Tanaka T, Soriano MA, and Grusby MJ (2005). SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22, 729-736.
8. Mi Z, Guo H, Wai PY, Gao C, and Kuo PC (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and UPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27, 1134-1145.
9. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, and Fu XY (1996). Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272, 719-722.
10. Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G, Abramson SB, Denhardt DT, and Amin AR (2001). Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum 44, 578-584.
11. Craig AM and Denhardt DT (1991). The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 100, 163-171.
12. Denhardt DT and Guo XJ (1993). Osteopontin: a protein with diverse functions. FASEB J 7, 1475-1482.
13. Senger DR, Asch BB, Smith BD, Perruzzi CA, and Dvorak HF (1983). A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 302, 714-715.
14. Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, and Tenen DG (1988). Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 48, 5770-5774.
15. Bautista DS, Xuan JW, Hota C, Chambers AF, and Harris JF (1994). Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269, 23280-23285.
16. Bromberg J and Darnell JE Jr (2000). The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473.
17. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, and Darnell JE Jr (1996). Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 93, 7673-7678.
18. Gooch JL, Herrera RE, and Yee D (2000). The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ 11, 335-342.
19. 1 cell cycle arrest mediated by the type I interferons. J Interferon Cytokine Res 17, 11-15.
20. Shuai K and Liu B (2003). Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3, 900-911.
21. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, et al. (1997). A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924.
22. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, et al. (1997). A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921.
23. Haque SJ, Harbor P, Tabrizi M, Yi T, and Williams BR (1998). Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem 273, 33893-33896.
24. You M, Yu DH, and Feng GS (1999). Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19, 2416-2424.
25. Bousquet C, Susini C, and Melmed S (1999). Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest 104, 1277-1285.
26. Ungureanu D and Silvennoinen O (2005). SLIM Trims STATs: ubiquitin E3 ligases provide insights for specificity in the regulation of cytokine signaling. Sci STKE 2005, e49.
27. Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, Nicholson SE, Hilton DJ, O'Neill LA, and Hertzog PJ (2006). Suppressor of cytokine signaling 1 negatively regulates toll-like receptor signaling by mediating Mal degradation. Nat Immunol 7, 148-155.
28. Loughran G, Healy NC, Kiely PA, Huigsloot M, Kedersha NL, and O'Connor R (2005). Mystique is a new insulin-like growth factor-I - regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses anchorage-independent growth. Mol Biol Cell 16, 1811-1822.